Literature DB >> 22866095

Radio-sensitization of the murine osteosarcoma cell line LM8 with parthenolide, a natural inhibitor of NF-κB.

Kenjiro Sugiyasu1, Katsuhiko Nanno, Noriyuki Tamai, Nobuyuki Hashimoto, Yuki Kishida, Hideki Yoshikawa, Akira Myoui.   

Abstract

Nuclear factor (NF)-κB has been shown to be associated with cancer resistance to radiotherapy (RT), and is constitutively active in the murine osteosarcoma cell line, LM8. Parthenolide has been reported to show antitumor activity through inhibition of the NF-κB pathway. In this study, we investigated the radio-sensitizing activity of parthenolide. We established Luc-LM8, a stable transfectant reporter construct of NF-κB transcriptional activity into LM8. Luc-LM8 maintained the malignancy observed with LM8. In vitro, Luc-LM8 cells were cultured with or without parthenolide treatment, irradiated, and subjected to cell viability and apoptosis assays. In vivo, to investigate whether parthenolide enhances radio-sensitivity of tumors, a tumor growth assay was conducted. Parthenolide enhanced the growth inhibitory effect of RT and induced the apoptosis of Luc-LM8 cells with RT in vitro. The in vivo tumor growth was significantly suppressed in the mice treated with parthenolide and RT. The present study suggests that parthenolide sensitizes Luc-LM8 cells to irradiation. Thus, parthenolide is a potential candidate for use as a potent radio-sensitizing drug for use in cancer RT.

Entities:  

Year:  2011        PMID: 22866095      PMCID: PMC3410451          DOI: 10.3892/ol.2011.277

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  39 in total

Review 1.  NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment.

Authors:  Nicolas Magné; Robert-Alain Toillon; Virginie Bottero; Céline Didelot; Paul Van Houtte; Jean-Pierre Gérard; Jean-François Peyron
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

Review 2.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

Authors:  Chikashi Nakanishi; Masakazu Toi
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Authors:  Rajasubramaniam Shanmugam; Vetrichelvan Jayaprakasan; Yesim Gokmen-Polar; Stephanie Kelich; Kathy D Miller; Michele Yip-Schneider; Liang Cheng; Poornima Bhat-Nakshatri; George W Sledge; Harikrishna Nakshatri; Qi-Huang Zheng; Michael A Miller; Timothy DeGrado; Gary D Hutchins; Christopher J Sweeney
Journal:  Prostate       Date:  2006-10-01       Impact factor: 4.104

Review 4.  Etiology of osteosarcoma.

Authors:  Bruno Fuchs; Douglas J Pritchard
Journal:  Clin Orthop Relat Res       Date:  2002-04       Impact factor: 4.176

5.  Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis.

Authors:  Jong-Hyun Kim; Lan Liu; Seung-Ok Lee; Yong-Tae Kim; Kyung-Ran You; Dae-Ghon Kim
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.

Authors:  Rajasubramaniam Shanmugam; Praveen Kusumanchi; Hitesh Appaiah; Liang Cheng; Peter Crooks; Sundar Neelakantan; Tyler Peat; James Klaunig; William Matthews; Harikrishna Nakshatri; Christopher J Sweeney
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

7.  In vivo imaging of gene transfer to the respiratory tract.

Authors:  Uta Griesenbach; Cuixiang Meng; Raymond Farley; Seng H Cheng; Ronald K Scheule; Mark H Davies; Paul C Wolstenholme-Hogg; Willem ten Hove; Paul van der Hoeven; Patrick L Sinn; Paul B McCray; Makoto Inoue; Duncan M Geddes; Mamoru Hasegawa; Gad Frankel; Siouxsie Wiles; Eric W F W Alton
Journal:  Biomaterials       Date:  2007-12-21       Impact factor: 12.479

8.  An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Authors:  Monica L Guzman; Randall M Rossi; Sundar Neelakantan; Xiaojie Li; Cheryl A Corbett; Duane C Hassane; Michael W Becker; John M Bennett; Edmund Sullivan; Joshua L Lachowicz; Andrew Vaughan; Christopher J Sweeney; William Matthews; Martin Carroll; Jane L Liesveld; Peter A Crooks; Craig T Jordan
Journal:  Blood       Date:  2007-09-05       Impact factor: 22.113

9.  Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide.

Authors:  Jing Wen; Kyung-Ran You; So-Youn Lee; Chang-Ho Song; Dae-Ghon Kim
Journal:  J Biol Chem       Date:  2002-07-31       Impact factor: 5.157

10.  Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells.

Authors:  Tomohide Mukogawa; Fumikazu Koyama; Masaaki Tachibana; Atsushi Takayanagi; Nobuyoshi Shimizu; Hisao Fujii; Masato Ueno; Hiroshi Matsumoto; Taku Takeuchi; Yoshiyuki Nakajima
Journal:  Cancer Sci       Date:  2003-08       Impact factor: 6.716

View more
  3 in total

1.  Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

Authors:  Alessandro De Vita; Laura Mercatali; Giacomo Miserocchi; Chiara Liverani; Chiara Spadazzi; Federica Recine; Alberto Bongiovanni; Federica Pieri; Davide Cavaliere; Valentina Fausti; Dino Amadori; Toni Ibrahim
Journal:  J Vis Exp       Date:  2018-04-11       Impact factor: 1.355

Review 2.  Traditional Medicinal Plants as a Source of Inspiration for Osteosarcoma Therapy.

Authors:  Liliya Kazantseva; José Becerra; Leonor Santos-Ruiz
Journal:  Molecules       Date:  2022-08-06       Impact factor: 4.927

3.  Relationship between TLR4 and NF-κB p65 protein expressions and clinical radiosensitivity of patients with esophageal squamous cell carcinoma.

Authors:  Hua Tang; Feng Wang; Xi-Fa Zhou; Jian Zhou; Ling Chen; Ju-Dong Luo; En-Ci Xu
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.